Anuh Pharma Limited has informed the Exchange regarding 'Intimation Pursuant To Regulation 31A Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015'.
ANUHPHR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Anuh Pharma Limited reported FY2026 audited results with revenue from operations growing 16.6% year-on-year to Rs. 77,166 lakhs. However, profit after tax declined 13.3% to Rs. 4,105 lakhs compared to Rs. 4,735 lakhs in FY2025. EBITDA margin compressed to 8.56% from 10.64% in the prior year. The Board recommended a dividend of Rs. 1.50 per share (30% payout), subject to shareholder approval at the AGM on August 12, 2026. The company received requests from 9 promoter group shareholders holding approximately 9.5 lakh shares (0.95%) seeking re-classification from 'Promoter Group' to 'Public' category under Regulation 31A. The statutory auditor issued an unmodified opinion, confirming clean financials. Operating cash flow turned negative at Rs. 301 lakhs primarily due to a significant increase in inventories (up Rs. 7,327 lakhs). A 1:1 bonus issue was completed in July 2025.
Revenue growth of 16.6% was offset by margin compression and PAT decline, resulting in lower profitability year-on-year. The negative operating cashflow and inventory build-up warrant monitoring. Promoter re-classification requests are minor (under 1%) but signal potential further changes in shareholding structure. Dividend payout remains modest at 30%.